Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Exon 20 insertion (Ex20Ins) mutations in EGFR and HER2 are prevalent in non-small cell lung cancer (NSCLC).
• Current EGFR and HER2 inhibitors show limited efficacy against Ex20Ins mutations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To discover and characterize potent and broadly effective inhibitors targeting EGFR and HER2 Exon 20 insertion mutations.
• To explore novel binding interactions for improved inhibitor design.

Main Methods:

• Co-crystal structure analysis of an inhibitor with wild-type EGFR.
• In vitro assessment of compound efficacy in inhibiting proliferation and signaling pathways in cell lines with EGFR/HER2 Ex20Ins mutations.
• Comparison with existing therapies like afatinib.

Main Results:

• Discovery of novel compounds demonstrating high potency against EGFR and HER2 Ex20Ins mutants.
• Identification of a unique hydrophobic interaction involving a 4-fluorobenzene ring in the EGFR binding site.
• Compound 1a showed superior inhibition compared to afatinib in relevant cell models, including a patient-derived lung cancer cell line.

Conclusions:

• The identified compounds represent promising therapeutic candidates for NSCLC patients with EGFR/HER2 Ex20Ins mutations.
• Exploiting the deep hydrophobic pocket offers a viable strategy for developing next-generation inhibitors.
• Further development of these inhibitors could address unmet clinical needs in NSCLC treatment.